| Gene symbol | TNFRSF17 | Synonyms | BCM, BCMA, CD269, TNFRSF13A | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p13.13 | dbXrefs | |
| Description | TNF receptor superfamily member 17 | ||||
| Gene symbol | GPRC5D | Synonyms | None | Type of gene | protein-coding |
| Chromosome | 12 | Map location | 12p13.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | G protein-coupled receptor class C group 5 member D | ||||
| GTO ID | GTC3890 |
| Trial ID | NCT06429150 |
| Disease | Multiple Myeloma | Plasmacytoma |
| Altered gene | BCMA|GPRC5D |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | BCMA/GPRC5D CAR-T cells |
| Phase | Phase1|Phase2 |
| Recruitment status | Recruiting |
| Title | Frontline Management of High-Risk Multiple Myeloma or Plasmacytoma With BCMA and GPRC5D Combination CAR-T Cell Therapy |
| Year | 2024 |
| Country | China|Russian Federation |
| Company sponsor | Shenzhen Geno-Immune Medical Institute |
| Other ID(s) | GIMI-IRB-24001 |
| Cohort 1 | |||||||
|
|||||||